Whether CD4+ CTLs collaborate with DN3 B cells in tumor immunity remains undetermined, despite these observations having been consistently identified in the pathogenesis of IgG4-RD, systemic sclerosis, fibrosing mediastinitis, and COVID-19. This evidence concerns the gene CD4 and systemic sclerosis.